Nektar Therapeutics NKTR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -284.2%-123pp | -297.1%-169pp | -204.5%-23.8pp | -172.9%+17.2pp | -160.8%+34.2pp | |
| Returns | ||||||
| Return on invested capital | -35.4%+39.8pp | -86%-23.8pp | -71%+0.8pp | -93.2%-26.6pp | -75.2%-18.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.2×-0.1× | 0.2×0.0× | 0.3×0.0× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 10.2×+7.0× | 5×+0.7× | 4.2×0.0× | 2.6×-2.5× | 3.2×-2.9× | |
| Per Share | ||||||
| Book value per share | $23.29+2,285% | $5.32+20.2% | $4.49+28.2% | -$1.72-130% | $0.98+50.2% | |
| Valuation | ||||||
| Market capitalization | $2.06B+1,531% | $860.04M+401% | $1.08B+299% | $303.35M+25.6% | $126.55M-29.1% | |
| Price / sales | 37.1×+35.7× | 15.6×+13.8× | 17.3×+14.4× | 4×+1.5× | 1.5×-0.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Nektar Therapeutics (NKTR) runs a 100.0% gross margin and a -242.0% operating margin, with a -284.2% net margin.
- Where do Nektar Therapeutics's ratios come from?
- Every ratio is computed from Nektar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
